The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
January 17th 2025
These drugs are set to revolutionize their respective disease states in 2025.
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
Navigating Parkinson Disease: Innovative Approaches to Mitigate OFF Episodes
1.0 Credit / Neurology
View More
The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Setti...
1.25 Credits / Neurology
View More
Addressing the Unmet Needs in the Management of Myasthenia Gravis: The Role of New and Emerging Therapies
1.5 Credits / Neurology
View More
In-Depth Insights and Application in the Management of Immunoglobulin Therapy
1.0 Credit / Neurology, Immunology
View More
Overview and Burden of Migraine
0.5 Credit / Neurology
View More
The Evolving Treatment Landscape of Migraine
0.5 Credit / Neurology
View More
The Role of the Pharmacist Migraine Management
0.5 Credit / Neurology
View More
FDA Committee Does Not Recommend Approval of Aducanumab for Alzheimer Disease
November 9th 2020A final vote that assessed whether the findings from the EMERGE trial served as primary evidence for the efficacy of aducanumab in Alzheimer disease was 10–0 that the trial did not provide evidence.
Read More
New Migraine Drugs Target Triptan Contraindication Population
November 5th 2020The current acute treatments for migraines have shown efficacy and safety, however, approximately one-third of people do not respond, cannot use these options due to contraindications, or report dissatisfaction in therapy.
Read More
Specialty Drug Pipeline Poised to Offer Many New Therapies in the Coming Year
September 21st 2020There were a number of FDA approvals in 2019 that were either the first new therapies or first in class approved for certain conditions, and the specialty pipeline is continuing to grow at a rapid pace.
Read More
Visual Impairment May Be Early Risk Factor for Dementia
September 11th 2020Although there is no underlying mechanism specifically associating cognitive and visual impairment, the investigators noted that the relationship between cognitive and visual function is likely bidirectional and multifactorial.
Read More
Risk of Cardiovascular Disease Is Associated with Cognitive Decline Later in Life
September 10th 2020Individuals with a higher risk of cardiovascular disease (CVD) demonstrate an increase in cognitive decline, including a rise in the typical markers of Alzheimer disease, according to the results of a recent study.
Read More